Targeted adenovirus vectors

被引:138
作者
Mizuguchi, H
Hayakawa, T
机构
[1] Natl Inst Hlth Sci, Osaka Branch, Fundamental Res Labs Dev Med, Project 3, Osaka 5670085, Japan
[2] Natl Inst Hlth Sci, Tokyo 1588501, Japan
关键词
D O I
10.1089/1043034042431146
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recombinant adenovirus (Ad) vectors continue to be the preferred vectors for gene therapy and the study of gene function because they are relatively easy to construct, can be produced at high titer, and have high transduction efficiency. However, in some applications gene transfer with Ad vectors is less efficient because the target cells lack expression of the primary receptor, coxsackievirus and adenovirus receptor (CAR). Another problem is the wide biodistribution of vector in tissue following in vivo gene transfer because of the relatively broad tissue expression of CAR. To overcome these limitations, various approaches have been developed to modify Ad tropism. In one approach, the capsid proteins of Ad are modified, such as with the addition of foreign ligands or the substitution of the fiber with other types of Ad fiber, in combination with the ablation of native tropism. In other approaches, Ad vectors are conjugated with adaptor molecules, such as antibody and fusion protein containing an anti-Ad single-chain antibody (scFv) or the extracellular domain of CAR with the targeting ligands, or chemically modified with polymers containing the targeting ligands. In this paper, we review advances in the development of targeted Ad vectors.
引用
收藏
页码:1034 / 1044
页数:11
相关论文
共 110 条
[1]   Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration [J].
Akiyama, M ;
Thorne, SH ;
Kirn, D ;
Roelvink, PW ;
Einfeld, DA ;
King, CR ;
Wickham, TJ .
MOLECULAR THERAPY, 2004, 9 (02) :218-230
[2]   Blood clearance rates of adenovirus type 5 in mice [J].
Alemany, R ;
Suzuki, K ;
Curiel, DT .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2605-2609
[3]   CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors [J].
Alemany, R ;
Curiel, DT .
GENE THERAPY, 2001, 8 (17) :1347-1353
[4]   Initial interactions of subgenus D adenoviruses with a549 cellular receptors:: Sialic acid versus αv integrins [J].
Arnberg, N ;
Kidd, AH ;
Edlund, K ;
Olfat, F ;
Wadell, G .
JOURNAL OF VIROLOGY, 2000, 74 (16) :7691-7693
[5]   Adenovirus type 37 uses sialic acid as a cellular receptor [J].
Arnberg, N ;
Edlund, K ;
Kidd, AH ;
Wadell, G .
JOURNAL OF VIROLOGY, 2000, 74 (01) :42-48
[6]   Genetically targeted adenovirus vector directed to CD40-expressing cells [J].
Belousova, N ;
Korokhov, N ;
Krendelshchikova, V ;
Simonenko, V ;
Mikheeva, G ;
Triozzi, PL ;
Aldrich, WA ;
Banerjee, PT ;
Gillies, SD ;
Curiel, DT ;
Krasnykh, V .
JOURNAL OF VIROLOGY, 2003, 77 (21) :11367-11377
[7]   Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR [J].
Bewley, MC ;
Springer, K ;
Zhang, YB ;
Freimuth, P ;
Flanagan, JM .
SCIENCE, 1999, 286 (5444) :1579-1583
[8]   Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites [J].
Burmeister, WP ;
Guilligay, D ;
Cusack, S ;
Wadell, G ;
Arnberg, N .
JOURNAL OF VIROLOGY, 2004, 78 (14) :7727-7736
[9]   Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector [J].
Campos, SK ;
Parrott, MB ;
Barry, MA .
MOLECULAR THERAPY, 2004, 9 (06) :942-954
[10]   Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C [J].
Chillon, M ;
Bosch, A ;
Zabner, J ;
Law, L ;
Armentano, D ;
Welsh, MJ ;
Davidson, BL .
JOURNAL OF VIROLOGY, 1999, 73 (03) :2537-2540